The Pharma Letter podcast

Player FM - Internet Radio Done Right

추가했습니다 three 년 전

Simon Wentworth에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Simon Wentworth 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

This Is Woman's Work with Nicole Kalil

1
The Icelandic Art of Intuition with Hrund Gunnsteinsdóttir | 307 35:19

15일 전35:19

나중에 재생

리스트

35:19

We’ve turned intuition into a buzzword—flattened it into a slogan, a gut feeling, or a vague whisper we don’t always know how to hear. But what if intuition is so much more? What if it's one of the most powerful tools we have—and we’ve just forgotten how to use it? In this episode, I’m joined by Hrund Gunnsteinsdóttir , Icelandic thought leader, filmmaker, and author of InnSæi: Icelandic Wisdom for Turbulent Times . Hrund has spent over 20 years studying and teaching the science and art of intuition through her TED Talk, Netflix documentary ( InnSæi: The Power of Intuition ), and global work on leadership, innovation, and inner knowing. Together, we explore what intuition really is (hint: not woo-woo), how to cultivate it in a culture obsessed with logic and overthinking, and why your ability to listen to yourself might be the most essential skill you can develop. In This Episode, We Cover: ✅ Why we’ve misunderstood intuition—and how to reclaim it ✅ Practical ways to strengthen your intuitive muscle ✅ What Icelandic wisdom teaches us about inner knowing ✅ How to use intuition during uncertainty and decision-making ✅ Why trusting yourself is an act of rebellion (and power) Intuition isn’t magic—it’s a deep, internal guidance system that already exists inside you. The question is: are you listening? Connect with Hrund: Website: www.hrundgunnsteinsdottir.com TedTalk: https://www.ted.com/talks/hrund_gunnsteinsdottir_listen_to_your_intuition_it_can_help_you_navigate_the_future?utm_campaign=tedspread&utm_medium=referral&utm_source=tedcomshare Newsletter: https://hrundgunnsteinsdottir.com/blog/ LI: www.linkedin.com/in/hrundgunnsteinsdottir IG: https://www.instagram.com/hrundgunnsteinsdottir/ Book: InnSæi: Icelandic Wisdom for Turbulent Times Related Podcast Episodes: How To Breathe: Breathwork, Intuition and Flow State with Francesca Sipma | 267 VI4P - Know Who You Are (Chapter 4) Gentleness: Cultivating Compassion for Yourself and Others with Courtney Carver | 282 Share the Love: If you found this episode insightful, please share it with a friend, tag us on social media, and leave a review on your favorite podcast platform! 🔗 Subscribe & Review: Apple Podcasts | Spotify | Amazon Music…

The Pharma Letter Podcast

시리즈 홈•Feed

The Pharma Letter Podcast provides in-depth discussion and analysis focused on key trends, companies and events in the pharmaceutical and biotech industries. Our guests come from a broad array of sectors and business functions, from early stage research in biopharmaceuticals, to patient engagement and marketing, supply chain management and life sciences investing. Podcasts are typically 20-30 minutes in length and are released approximately once every two weeks.

31 에피소드

#News #Simon Wentworth #Biotech #Pharma #Pharmaceutical #Editorial #Analysis #Prescription Drugs #Medicine #Patient

The Pharma Letter Podcast

updated 14일 전

시리즈 홈•Feed

31 에피소드

#News #Simon Wentworth #Biotech #Pharma #Pharmaceutical #Editorial #Analysis #Prescription Drugs #Medicine #Patient

모든 에피소드

The Pharma Letter Podcast

1
ICON's AI strategy: faster, smarter trials 15:59

14일 전15:59

나중에 재생

리스트

15:59

This week on The Pharma Letter Podcast, we are joined by Tony Clarke, senior VP of IT digital operations at ICON (Nasdaq: ICLR). As a leader in digital transformation within clinical research, Tony has been at the forefront of implementing AI-driven solutions to enhance drug development. A global contract research organization (CRO), ICON has been tracking industry attitudes toward digital innovation. In 2019, the company conducted a survey to gauge investment trends in new technologies, and now, five years later, a new study reveals how perceptions and adoption have evolved. While the rise of AI, particularly generative AI, has dominated the debate across industries, we consider how it is truly shaping clinical research, including potential barriers to adoption. We’ll also talk about how digital tools are driving efficiencies in drug development, and what the future holds for technology in clinical trials. Partnered content.…

The Pharma Letter Podcast

1
How real-time data could transform clinical trials 15:14

10 weeks 전15:14

나중에 재생

리스트

15:14

In this week’s podcast, we welcome Iddo Peleg, CEO and co-founder of Yonalink, who provides insights into the current and future state of the clinical trial industry. As we move headlong into 2025, a year that appears set to be characterized by global economic and political turmoil, Iddo discusses major trends in the industry, including challenges posed by the COVID-19 aftermath and the potential impacts of regulatory upheaval on clinical trials. He also outlines how Yonalink’s technology, which streams data from electronic health records to clinical trial databases, can dramatically reduce timelines and improve accuracy in clinical studies. The conversation delves into the practicalities and potentials of decentralized and distributed clinical trials, offering advice to young biotech startups on leveraging the right technology for innovation.…

The Pharma Letter Podcast

1
Japanese pharma in the UK 19:43

14 weeks 전19:43

나중에 재생

리스트

19:43

In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma. Tokyo-headquartered Astellas (TYO: 4503) has developed a strong portfolio in urology, oncology and immunology, most recently with US FDA approval for Vyloy (zolbetuximab), a key addition to its cancer treatments. It’s one of many Japanese companies with a strong presence in the UK, represented nationally by the Japanese Pharmaceutical Group, of which Jackie is the current chair. We’ll get into the details of a recent visit from the JPG to the House of Lords, as well as her view on some of the challenges and opportunities that have arisen in the years since Brexit.…

The Pharma Letter Podcast

1
How can we use AI to program antibodies? 16:25

27 weeks 전16:25

나중에 재생

리스트

16:25

This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. We are joined by Yanay Ofran, chief executive and founder of Israel-based Biolojic Design, a company that is working on programmable antibodies. Biolojic's platform has already yielded a first-of-its-kind computationally designed antibody, now in Phase II trials, as well as a pipeline aimed at autoimmune and inflammatory conditions. The firm has also forged collaborations with major players in the industry, including fellow Israeli firm Teva (NYSE: TEVA), as well as Eli Lilly (NYSE: LLY) and Germany’s Merck KGaA (MRK: DE).…

The Pharma Letter Podcast

1
Breakthroughs in MASH, with 89bio CEO 22:19

47 weeks 전22:19

나중에 재생

리스트

22:19

This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH. It’s a high area of unmet medical need, with over 20 million diagnosed cases across Europe and the USA, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development. One company working in this area is San Francisco-based 89bio (Nasdaq: ETNB), which has a candidate now in Phase III, pegozafermin, and in this episode we are joined by the company’s chief executive, Rohan Palekar. We are also joined by Dr Arun Sanyal, who is Professor of Medicine at VCU Health and founder of the Liver Trust.…

The Pharma Letter Podcast

1
How to develop cancer drugs faster, with Ellipses Pharma 22:50

1 year 전22:50

나중에 재생

리스트

22:50

This week we are speaking with the chief executive of British drug development company Ellipses Pharma. Founded in 2018 to create new cancer therapies, the firm is following a unique multimodal approach to clinical development, leveraging a variety of technologies. That’s not the only way that Ellipses is rethinking drug development. The company uses a consultative model to provide an unbiased vetting process for candidates, with the goal of de-risking initial asset selection. Ellipses also wants to make sure that capital is invested in the most efficient way, pursuing a portfolio-based strategy which ensures uninterrupted development capital for each asset. Our guest on the show is Ellipses CEO and co-founder, Dr Rajan Jethwa.…

The Pharma Letter Podcast

1
CRO sector surges in bio revolution 12:46

2 years 전12:46

나중에 재생

리스트

12:46

In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish. In this episode of The Pharma Letter Podcast, we chat with the company’s chief commercial officer, George McMillan. Like many in the industry, the Dublin-headquartered clinical research organization (CRO) has sought to grow in size to take advantage of increasing demand for its services. A coming together of numerous advances in biotechnology over recent years has led to a new wave of innovation in the life sciences. Much of the innovation has come from smaller biotech firms, sometimes incubated by hands-on investment groups dedicated to nurturing early-stage science. But such start-ups need support to progress into clinical-stage development and beyond, with regulators keeping a close eye on the development and manufacture of new technologies. This is one area in which CROs and CDMOs have picked up the slack. Another trend is the increasing desire on the part of large pharmaceutical players to divest non-core parts of the business and focus on their key strengths - providing an opportunity for a company like ICON to pick up new partnerships and development opportunities. As new biologics and cell and gene therapies start to have a real impact on people’s lives and health, the degree of specialism required has enabled some companies to establish themselves as leading experts in certain areas. The future looks bright, and as the impact of artificial intelligence is increasingly felt in this sector, there is surely plenty more to come.…

The Pharma Letter Podcast

1
Lilly looks to lead in Alzheimer's 17:20

2 years 전17:20

나중에 재생

리스트

17:20

With an Accelerated nod for Aduhelm (aducanumab) and now full approval for Leqembi (lecanemab) in the USA, Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523) have overturned decades of failure in Alzheimer’s. But at the annual meeting of the Alzheimer’s Association (AAIC), it’s another neurology heavyweight taking center stage, as Eli Lilly (NYSE: LLY) makes clear its intention to remain a leader in the treatment of this challenging disease. At the AAIC in Amsterdam, we’re speaking with two key figures from the development program for donanemab, a candidate which could slow cognitive decline for millions of people with early Alzheimer’s, while generating billions in annual revenues. Lilly is presenting full results from a key Phase III trial of its antibody, which like Leqmebi, clears aberrant proteins from the brain with the goal of combatting neurodegeneration. There are important differences between the way the two molecules work, however, and Lilly is confident its approach, which includes limited duration dosing, offers the best chance of success. The new data, which form part of a regulatory submission for approval in the USA, seem to bear this out. As with other therapies in this class, all eyes will be on safety, and Lilly hopes that “treating to clear,” and then holding off on dosing, could help avoid side effects. Like Eisai , Lilly is also interested in developing a subcutaneous treatment in future, with early data for another molecule, remternetug, showing strong potential in this regard. We discuss all of this and more, in Episode 24 of The Pharma Letter Podcast.…

The Pharma Letter Podcast

1
AAIC preview with Eisai deputy CCO Michael Irizarry 22:43

2 years 전22:43

나중에 재생

리스트

22:43

In the runup to the annual meeting of the Alzheimer’s Association, this week we are speaking with Michael Irizarry, deputy chief clinical officer at Eisai US. At the event in July, there will be plenty to discuss, with recent new data from Eli Lilly (NYSE: LLY) suggesting its anti-amyloid candidate, donanemab, is likely to provide healthy competition for Eisai's (TYO: 4523) own Alzheimer’s product, lecanemab - marketed in the USA as Leqembi. Like Lilly, Eisai has been a pioneer in neurology, sticking with its Alzheimer’s research even when times were tough and it looked like a clinical breakthrough would never come. That we are now talking about potentially three approved products for early Alzheimer’s shows how quickly development has advanced - as both Lilly and Eisai look ahead to the possibility of offering more beneficial subcutaneous treatments in future. In the podcast this week, we will discuss Eisai’s upcoming presentations at AAIC and consider what the future might hold for the treatment of Alzheimer’s.…

The Pharma Letter Podcast

1
A new way to innovate, from Flagship Pioneering 23:37

2 years 전23:37

나중에 재생

리스트

23:37

Set against a backdrop of foundering confidence in biotech stocks, the success of some companies incubated by Massachusetts-based Flagship Pioneering has been remarkable. Flagship has invested billions of dollars getting startups off the ground, many of which, such as Foghorn Therapeutics (Nasdaq: FHTX), Codiak Biosciences (Nasdaq: CDAK) and Rubius (Nasdaq: RUBY), have gone on to become publicly-traded companies. Moderna Therapeutics (Nasdaq: MRNA), the poster child for the firm’s strategy, has generated tens of billions of dollars while saving millions of lives with its mRNA-based coronavirus vaccine. Not content to propagate life-changing technologies at over 40 new startups, Flagship now hopes to reinvent the way commercial drugmakers engage with biotech platforms, launching Pioneering Medicines in 2020. The idea is to build a portfolio of cutting edge medicines by identifying novel therapeutic approaches within Flagship’s fleet of companies. Led by former Bristol Myers Squibb (NYSE: BMY) veteran Paul Biondi, executive partner at Flagship since 2019, the firm’s new venture has already scored a major partnership with Danish diabetes giant Novo Nordisk (NOV: N). The aim is to link with big players in the industry to carry forward emerging candidates into late-stage development. On this week’s episode of The Pharma Letter Podcast, we speak with Mr Biondi to understand more about his work at Pioneering Medicines, and gain an insight into broader industry trends.…

The Pharma Letter Podcast

1
Will radical new EU regs hobble industry? 22:56

2 years 전22:56

나중에 재생

리스트

22:56

A draft of the European Commission’s ongoing review of pharmaceutical legislation has leaked, prompting a bitterly-worded reaction from drugmakers, which accuse legislators of “sabotaging” the industry. There is no doubt that the proposals represent serious change. Maarten Meulenbelt, partner and expert on EU regulatory affairs at Sidley Austin, describes them as the most far-reaching for decades. On this week’s episode of The Pharma Letter Podcast, Mr Meulenbelt will walk us through the leaked draft and outline the most significant impacts, good and bad. Some of the measures to be considered include: generally shorter periods of exclusivity for novel medicines; a requirement that new drugs must launch region–wide within two years; and the introduction of a voucher system to encourage the development of new antibiotics. The European Commission is also apparently proposing to simplify the drug application process, increase obligations on drugmakers to report shortages and bring in more foreign inspections. Of course, whatever the final proposals turn out to be when they are published at the end of April, they will likely change again, with the European Parliament and the EU Council next in line to debate and revise the document. No doubt, there will be plenty of chances for the industry to have its say before then.…

The Pharma Letter Podcast

1
Galapagos update—with CEO Paul Stoffels 20:15

2 years 전20:15

나중에 재생

리스트

20:15

This week on The Pharma Letter Podcast, we are joined by Galapagos (Euronext: GLPG) chief executive Paul Stoffels. After an illustrious career as chief scientific officer at Johnson & Johnson (NYSE: JNJ), Dr Stoffels is ready for a new chapter in his home country of Belgium. His instalment as Galapagos CEO is also a kind of homecoming. Founded in 1999, the firm emerged from a joint venture between Crucell and Tibotec, an infectious disease specialist for which Dr Stoffels served as chair, before the company was acquired by J&J in 2002. While the company has a strong balance sheet and a promising pipeline, Galapagos has had its share of ups and downs in recent years, including late-stage failures and a rebuff from the US regulator for a JAK inhibitor partnered with Gilead Sciences (Nasdaq: GILD). With his feet barely under the desk, Dr Stoffels has been busy moving on from disappointments connected with the Gilead partnership, with a series of M&A moves. The acquisition of CellPoint and AboundBio will boost access to next-generation cell therapies and help the firm in its stated aim of bringing three differentiated CAR-T candidates into clinical development within three years. In this week’s episode of the podcast, we’ll ask Dr Stoffels about what motivated him to leave J&J, and what he has planned for Galapagos in the coming year.…

The Pharma Letter Podcast

1
US midterms and beyond: the outlook for pharma 18:06

2 years 전18:06

나중에 재생

리스트

18:06

The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the next Congress. Analysts, having expected a stronger showing for Republicans, put some of the blame on former president Donald Trump, whose endorsements and active involvement in campaigning were said to frighten off moderates. In this week’s episode of The Pharma Letter Podcast, we are joined by Stephanie Kennan, senior VP for federal public affairs at McGuireWoods Consulting, for a discussion on the possible implications. We’ll consider the likely course of future life sciences legislation, in particular the additional provisions which were omitted from the pared back, so-called “skinny” user fee reauthorization in September. We'll also take a quick look ahead to 2024. As Florida’s Ron DeSantis basks in the triumph of his gubernatorial campaign, a run at the presidency now looks inevitable, and bookmakers are putting him above Mr Trump as favorite to win power - albeit with a long way to go until polling day. We’ll discuss what a DeSantis White House might look like for the life sciences industry.…

The Pharma Letter Podcast

1
Focus on rare liver diseases, with Albireo CEO Ron Cooper 16:56

3 years 전16:56

나중에 재생

리스트

16:56

*Partnered content In Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for rare pediatric liver diseases. Led by president and chief executive officer Ron Cooper, Albireo (Nasdaq: ALBO) has since 2021 boasted both US and EU approval for the novel bile acid modulator Bylvay (odevixibat). The oral medicine addresses an unmet need by providing the first non-surgical treatment option for people with progressive familial intrahepatic cholestasis (PFIC), a rare genetic disorder affecting young children that causes progressive, life threatening liver disease. Bylvay is approved for the treatment of pruritus in PFIC in the USA, and for PFIC in Europe. The company has also recently announced positive top-line results from the Phase III ASSERT study, which is testing Bylvay in Alagille syndrome (ALGS), another rare genetic disorder. Approval in ALGS would open up another source of revenue for the product, and offer hope for families impacted by this serious condition, which affects multiple organ systems including the liver and heart. Estimates vary for the therapy’s peak revenue potential, but most analysts suggest the product will be able to generate hundreds of millions in annual sales, should all go according to plan. As well as transforming the treatment of rare conditions with a high disease burden, such an outcome would enable the company to more fully explore the science of IBAT inhibition, an approach which it believes has great potential in a wide range of cholestatic liver diseases. In this week’s episode of The Pharma Letter Podcast, I’m pleased to be joined by Ron Cooper, for a discussion of his company’s clinical goals and strategic focus.…

The Pharma Letter Podcast

1
Inflation Reduction Act: quick take 12:19

3 years 전12:19

나중에 재생

리스트

12:19

As President Joe Biden signs the Inflation Reduction Act into law, drugmakers in the USA are poring over the likely impact on drug prices, and how best to respond to its enactment. The legislation passed in the US Congress with Vice President Kamala Harris casting the decisive vote in an otherwise deadlocked Senate. That evident lack of bipartisanship put the kibosh on Democrats’ more ambitious plans, with the new law representing a greatly watered down version of the original $3.5 trillion Build Back Better plan. Democrats have had to scrap limits on certain drug price increases above inflation, for example, with this provision applying only to drugs paid for by the federal insurance fund Medicare. Nonetheless, the Inflation Reduction Act is a very significant piece of legislation, unlocking subsidies for so-called Obamacare recipients in order to reduce annual premiums by $800 for around 13 million people. The new law also finally realizes a long-held ambition for Democrats, empowering Medicare’s administrators to negotiate certain drug prices directly, up to a point. In this week's episode of The Pharma Letter Podcast, we take a quick look at the Act’s provisions and the likely impact on drugmakers with Stephanie Kennan, a senior member of the Federal Public Affairs group at McGuireWoods Consulting.…

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

500개 이상의 주제를 청취

The Pharma Letter Podcast와 비슷한 콘텐츠

Bounty Quick Size Paper Towels, White, 8 Family Rolls = 20 Regular Rolls (Packaging May Vary)

2025 - American Silver Eagle .999 Fine Silver with our Smyrnacoin Certificate of Authenticity Dollar Uncirculated US Mint

Amazon Basics Multipurpose Copy Printer Paper, 8.5 x 11 inches, 20 lb, 1 Ream, 500 Sheets, 92 Bright, White

들어볼 가치가 있는 팟캐스트

The Pharma Letter Podcast

The Pharma Letter Podcast

들어볼 가치가 있는 팟캐스트

플레이어 FM에 오신것을 환영합니다!

Minecraft

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

Bounty Paper Towels Quick Size, White, 16 Family Rolls = 40 Regular Rolls (Packaging May Vary)

Nespresso Capsules Vertuo, Variety Pack, Medium and Dark Roast Coffee, 30 Count Coffee Pods, Brews 7.8 oz.

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

The Pharma Letter Podcast와 비슷한 콘텐츠

빠른 참조 가이드